The revenue of drug maker, May & Baker, dropped 38.05 percent to N5.91billion in the third quarter of 2019 from N6.54bn in the corresponding period of 2018.
The company’s cost of sales reduced 9.63percent to N3.75bn from N4.15bn, while its distribution, sales, and marketing expenses stood a
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
